硬骨素(SOST)單克隆抗體
Monoclonal Antibody to Sclerostin (SOST)
VBCH; Sclerosteosis
- 編號(hào)MAC864Hu22
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))-
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 666 ¥ 1554 ¥ 2220 ¥ 5550 ¥ 22200
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)SOST的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別SOST。
用法
免疫印跡：0.2-2μg/mL;1:500-5000
免疫組織化學(xué)：5-20μg/mL;1:50-200
免疫細(xì)胞化學(xué)：5-20μg/mL;1:50-200
最佳稀釋倍數(shù)最終由用戶決定。
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| EPC864Hu61 | 硬骨素(SOST)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPC864Hu01 | 硬骨素(SOST)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC864Hu01 | 硬骨素(SOST)多克隆抗體 | WB; IHC; ICC; IP. |
| MAC864Hu22 | 硬骨素(SOST)單克隆抗體 | WB; IHC; ICC; IP. |
| SEC864Hu | 硬骨素(SOST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| MEC864Hu | 硬骨素(SOST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC864Hu | 硬骨素(SOST)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Life Sciences | Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes [PubMed: 23357248] |
| Calcified Tissue International | Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes [Pubmed: 23247536] |
| Arthritis Res Ther. | Serum Sclerostin in Adult High-Activity Patients with Juvenile Idiopathic Arthritis [Pubmed:Pmc4236454] |
| Korean J Intern Med | Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use [Pubmed:Pmc4219971] |
| Journal of Bone and Mineral Research | The Anti-Osteoanabolic Function of Sclerostin is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5 [Pubmed:25640331] |
| FASEB J. | DMP-1-mediated [PubMed: 26481310] |
| Pharmacology | Effect of Mirtazapine on Rat Bone Tissue after Orchidectomy [PubMed: 25871861] |
| European?Journal of Pharmacology | The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism [Pubmed:29428468] |
| EFFECTS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG TREATMENT ON PERIARTICULAR BONE REMODELING IN RHEUMATOID AND PSORIATIC?… [:] | |
| Journal of Clinical and Translational Endocrinology | Dobesity: relationship between vitamin d deficiency, obesity and sclerostin as a novel biomarker of bone metabolism [] |
| JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | Circulating Osteocyte‐Related Biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: their impact in?… [Pubmed: 33065276] |
| Oxid Med Cell Longev | Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats [34373766] |
